HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

/in

Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M, Buning H, Schwartz O, Knops E, Kaiser R, Seaman MS, Wilson JM, Rice CM, Ploss A, Bjorkman PJ, Klein F, Nussenzweig MC. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. 2013, 110(41):16538-43.

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

/in

Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013, 153(1):126-38.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

/in , ,

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 2013; 207:248-256.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.

/in

Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium. Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013, 10:347.

Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1 neutralizing activity.

/in

Song R, Oren DA, Franco D, Seaman MS, Ho DD. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1 neutralizing activity. Nat. Biotechnol. 2013, 31(11):1047-52.

Comparative analysis of SIV Gag specific effector and memory CD8 T cells induced by different adenovirus vectors.

/in

Tan WG, Jin HT, West EE, Penaloza-Macmaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R. Comparative analysis of SIV Gag specific effector and memory CD8 T cells induced by different adenovirus vectors. J. Virol. 2013; 87:1359-1372.

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

/in

Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, Destefano J, Seaman MS, Tomaras GD, Montefiori DC, Scheif WR, Sattentau QJ. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J. Virol. 2013, 87(18): 10163-72.

The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.

/in

Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai, Larue RC, Patel PA, Mitsuya M, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2013 May 31;288(22:15813-20. doi: 10.1074/jbc.M112.443390. Epub 2013 Apr 24. PubMed PMID: 23615903; PubMed Central PMCID: PMC3668738.

A global approach to HIV-1 vaccine development.

/in

Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev. 2013 Jul;254(1):295-304. doi: 10.1111/imr.12073. Review. PubMed PMID: 23772627; PubMed Central PMCID: PMC3693768.

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

/in

Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M Jr, Chertova E, Giavedoni LD, O’Connor DH, Lifson JD, Keele BF. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J. Virol. 2013; 87:4584-4595.